237690 - ST Pharm Co., Ltd.

237690 Summary

Biopharma

Stock Price & Overview

₩101,200 +2,200 (+2.22%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩101,200 ≈ US$72 · Market cap ₩2.1tn (≈ $1.5bn)

237690 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	331.7	273.8	285.0	249.3	165.6	—	93.3	97.7	202.8	200.4	138.1
Cost of Revenue	195.5	177.6	172.9	160.4	107.9	—	94.9	95.0	123.0	107.4	86.8
Gross Profit	136.2	96.2	112.1	88.9	57.7	—	-1.6	2.8	79.8	93.0	51.3
Selling, General & Administrative	81.3	68.5	78.6	71.1	52.2	—	25.1	18.4	17.9	15.4	16.8
Operating Income	54.9	27.7	33.5	17.9	5.6	—	-26.7	-15.6	61.8	77.6	34.5
Finance Income	17.8	35.3	9.4	15.0	5.6	—	3.1	3.4	3.2	8.1	1.8
Finance Costs	13.4	18.6	19.7	13.6	6.3	—	1.3	0.4	4.3	3.5	7.3
Pretax Income	58.7	42.7	23.4	19.2	1.3	—	-25.0	-13.4	59.2	80.5	35.6
Income Tax Expense	4.2	10.3	5.8	1.7	-2.1	—	-6.4	-4.1	14.2	19.1	10.4
Net Income	54.6	32.5	17.5	17.5	3.4	—	-18.5	-9.3	45.0	61.4	25.2
Total Comprehensive Income	55.8	32.3	19.4	19.5	5.1	—	-18.9	-10.2	45.7	58.2	29.5

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	782.6	721.9	675.4	578.7	498.6	341.1	341.1	345.5	381.5	367.8	232.4
Current Assets	372.7	330.1	348.4	271.3	244.1	144.2	144.2	167.3	225.2	224.9	95.8
Cash & Cash Equivalents	30.5	63.4	50.1	50.2	39.2	12.8	12.8	47.7	72.3	55.2	11.8
Inventories	169.5	127.0	120.7	107.6	80.8	40.9	40.9	40.7	58.0	91.4	58.7
Trade Receivables	96.7	67.8	120.6	94.2	62.9	35.4	35.7	15.9	30.3	13.4	13.2
Non-current Assets	409.9	391.8	327.1	307.4	254.4	196.9	196.9	178.2	156.3	142.9	136.6
Property, Plant & Equipment	357.2	336.1	277.0	254.3	209.1	171.7	172.5	169.1	151.6	138.4	134.1
Intangible Assets	17.0	16.5	13.5	12.5	12.6	8.0	8.0	1.4	1.2	1.1	1.1
Total Liabilities	189.6	218.9	288.5	229.5	172.5	37.4	37.4	13.9	30.4	54.5	121.5
Current Liabilities	164.8	133.3	83.7	179.2	52.6	16.2	16.2	10.0	28.6	51.5	108.2
Non-current Liabilities	24.8	85.6	204.8	50.3	120.0	21.2	21.2	4.0	1.8	3.1	13.3
Total Equity	593.0	503.0	386.9	341.1	326.0	303.7	303.7	331.6	351.1	313.2	110.9
Share Capital	10.4	10.1	9.4	9.4	9.4	9.3	9.3	9.3	9.3	9.2	5.9
Retained Earnings	204.2	159.4	135.7	126.9	115.6	123.6	123.6	151.6	170.6	134.0	76.0

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	14.0	109.5	1.3	7.0	7.3	—	-30.5	10.8	54.4	50.8	35.8
Cash from Investing Activities	-26.3	-86.5	-82.4	-5.7	-8.0	—	-9.8	-26.8	-26.3	-93.2	-33.1
Purchase of Property, Plant & Equipment	47.1	82.8	43.2	60.5	51.8	—	6.2	27.2	27.7	16.0	22.1
Cash from Financing Activities	-20.1	-11.0	81.4	10.8	-0.1	—	5.3	-9.0	-9.1	85.2	6.6
Dividends Paid	10.1	9.4	9.4	9.4	0.0	—	9.3	9.3	9.2	2.9	1.0
Net Change in Cash	-32.4	12.0	0.3	12.1	-0.9	—	-35.0	-25.0	19.0	42.8	9.4

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	108.5	67.0	129.1	81.9	68.3	52.4	115.7	61.7	44.6	51.7
Cost of Revenue	69.4	35.8	81.2	44.9	36.2	33.2	76.3	39.2	29.3	32.7
Gross Profit	39.1	31.1	47.9	37.0	32.0	19.3	39.4	22.5	15.3	19.0
Selling, General & Administrative	20.8	19.6	21.7	22.3	19.1	18.2	16.6	16.4	18.3	17.1
Operating Income	18.3	11.5	26.3	14.7	12.9	1.0	22.8	6.1	-3.1	1.9
Finance Income	2.8	8.7	7.4	6.1	2.0	2.2	3.7	14.0	7.3	10.3
Finance Costs	2.4	3.1	4.2	-0.0	7.5	1.7	7.0	5.2	3.2	3.2
Pretax Income	18.1	17.7	29.3	21.0	6.9	1.6	19.4	14.9	0.9	7.5
Income Tax Expense	5.0	2.5	-1.7	3.5	1.5	0.9	7.0	1.2	-0.0	2.1
Net Income	13.2	15.2	31.0	17.5	5.4	0.7	12.4	13.7	0.9	5.4
Total Comprehensive Income	13.5	15.8	31.2	17.9	6.0	0.8	12.1	14.4	1.2	4.5

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	848.0	849.9	782.6	755.5	732.4	742.2	721.9	691.6	666.2	675.8
Current Assets	447.1	445.2	372.7	356.7	322.5	336.7	330.1	323.5	324.4	341.4
Cash & Cash Equivalents	53.8	111.3	30.5	44.3	41.7	24.8	63.4	41.0	29.5	71.1
Inventories	196.4	194.5	169.5	174.6	163.1	146.6	127.0	158.6	154.7	133.8
Trade Receivables	47.3	37.5	96.7	49.2	57.5	56.6	67.8	50.5	44.6	72.8
Non-current Assets	400.9	404.7	409.9	398.8	409.9	405.4	391.8	368.1	341.8	334.4
Property, Plant & Equipment	357.9	356.8	357.2	359.7	358.2	351.1	336.1	307.2	295.8	283.6
Intangible Assets	17.2	17.3	17.0	16.8	16.7	16.7	16.5	16.2	13.4	13.2
Total Liabilities	219.0	238.7	189.6	199.5	231.9	247.9	218.9	203.1	238.0	284.4
Current Liabilities	196.2	214.4	164.8	175.0	147.6	162.1	133.3	80.9	76.3	88.5
Non-current Liabilities	22.7	24.3	24.8	24.5	84.3	85.7	85.6	122.1	161.7	195.9
Total Equity	629.1	611.2	593.0	556.0	500.5	494.3	503.0	488.5	428.2	391.4
Share Capital	10.4	10.4	10.4	10.3	10.1	10.1	10.1	10.1	9.7	9.5
Retained Earnings	221.9	208.8	204.2	173.6	156.0	150.4	159.4	148.2	133.6	132.6

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	1.5	103.1	-21.2	29.2	-11.5	17.4	55.7	9.0	7.4	37.3
Cash from Investing Activities	-50.7	-27.3	11.6	-25.2	41.2	-54.0	-32.0	5.0	-45.0	-14.5
Purchase of Property, Plant & Equipment	6.0	9.0	5.7	14.6	6.0	20.8	34.5	17.4	18.1	12.8
Cash from Financing Activities	-7.6	4.0	-2.9	-3.1	-11.5	-2.6	-2.5	-2.2	-2.7	-3.5
Dividends Paid	—	—	0.0	0.0	—	—	0.0	0.0	—	—
Net Change in Cash	-56.9	79.8	-12.5	0.9	18.3	-39.2	21.2	11.7	-40.3	19.3

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

237690 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	331.7	+21.2%	+10.0%	—	+9.2%
Operating income	54.9	+98.4%	+45.5%	—	+4.8%
Net income	54.6	+68.1%	+46.0%	—	+8.0%
EPS	₩2,614	+68.1%	+46.0%	—	+8.0%
Operating cash flow	14.0	-87.2%	+25.8%	—	-9.0%
Shareholders' equity	593.0	+17.9%	+20.2%	+14.3%	+18.3%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

237690 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	41.1%	35.1%	39.3%	35.7%	34.9%	—
Operating margin	16.6%	10.1%	11.8%	7.2%	3.4%	—
Net margin	16.5%	11.9%	6.1%	7.0%	2.0%	—
Return on equity	10.0%	7.3%	4.8%	5.3%	1.1%	—
Return on assets	7.3%	4.6%	2.8%	3.3%	0.8%	—
Operating cash flow / revenue	4.2%	40.0%	0.5%	2.8%	4.4%	—
Capex / revenue	14.2%	30.2%	15.2%	24.3%	31.3%	—

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 237690

Symbol	Last Price
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%
310210Voronoi, Inc.	₩153,000 +3.9%
214370Caregen Co., Ltd.	₩44,500 +1.5%
347850D & D Pharmatech, Inc.	₩49,200 +1.4%
226950Olix Pharmaceuticals, Inc.	₩95,900 +4.5%
140410Mezzion Pharma Co., Ltd.	₩65,000 +0.0%
068760Celltrion Pharm, Inc.	₩40,850 +0.0%
007390Naturecell Co., Ltd.	₩23,950 +0.2%
006280GC Biopharma Corp.	₩127,600 +0.5%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.